Global Ranibizumab Market Growth (Status and Outlook) 2023-2029

Global Ranibizumab Market Growth (Status and Outlook) 2023-2029

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.
LPI (LP Information)' newest research report, the “Ranibizumab Industry Forecast” looks at past sales and reviews total world Ranibizumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ranibizumab sales for 2023 through 2029. With Ranibizumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ranibizumab industry.
This Insight Report provides a comprehensive analysis of the global Ranibizumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ranibizumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ranibizumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ranibizumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ranibizumab.
The global Ranibizumab market size is projected to grow from US$ 3374.6 million in 2022 to US$ 1580.5 million in 2029; it is expected to grow at a CAGR of -10.3% from 2023 to 2029.
Global core ranibizumab manufacturers include Roche and Novartis etc. The Top 2 companies hold a share about 98%. North America is the largest market, with a share about 51%, followed by Europe and Asia Pacific with the share about 28% and 20%.
This report presents a comprehensive overview, market shares, and growth opportunities of Ranibizumab market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Glass Vial
Prefilled Syringe
Segmentation by application
Wet AMD
Complications of Diabetes
RVO
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Novartis

Please note: The report will take approximately 2 business days to prepare and deliver.